VCYT · Veracyte, Inc.
$42.31
+0.52 (+1.24%)
At close · Aug 21
Market Cap
$3.36B
Shares
80.39M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$42.31
Open$42.18
Day$41.10–42.54
52W close$28.61–60.49
Avg vol 30d1.3M
Short int6.9M · 8.5% float · 4.8d
Short vol72%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 31
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 31, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
−19%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
+18%
trailing
YTD return
+1%
this year
Relative strength
+6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $52 › 200d $43 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +77 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.53% of float · ▲ +2.8% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
367 holders — near 3-yr high, broad support
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
70%
expanding
EPS growth
+165%
Y/Y
Free cash flow
$126.6M
Valuation
P/E 29.9
below peers
Balance sheet
$362.6M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Total revenue
· 2026
$590M – $596M
prior FY $517.15M
midpoint +14.7% Y/Y
Testing revenue
· 2026
$576M – $582M
Adjusted EBITDA margin
· 2026
Non-GAAP
at least 26%
Prior guidance
period ended
· from the 8-K filed Nov 4, 2025
Testing revenue
· full year 2025
$484M – $487M
Total revenue
· full year 2025
$506M – $510M
Adjusted EBITDA as a percentage of revenue
· full year 2025
at least 25%
Guided vs delivered
· last 3 settled
Total revenue
full year 2025
guided $506M – $510M
$517.15M
Beat +1.8%
Total revenue
2024
guided $394M – $402M
$445.76M
Beat +12.0%
Revenue
2023
guided $352M – $354M
$361.05M
Beat +2.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
−19%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $52 › 200d $43 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +77 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.53% of float · ▲ +2.8% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
367 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $29
Now $42 · 43%
Range high $60
vs 200-day avg 0%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 86.76M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA as a % of Revenue non-GAAP | 30% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Afirma volume | 18,600 | second quarter of 2026 | — |
|
|
|||
| Decipher volume | 29,700 | second quarter of 2026 | — |
|
|
|||
| Non-GAAP Net Income non-GAAP | 86.44M | Six Months Ended June 30, 2026 | — |
| Testing volume | 48,389 | second quarter of 2026 | — |
|
|
|||
| Total volume | 50,967 | second quarter of 2026 | — |
|
|
|||
| Cash from operations | $35.2M | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCYT
this stock
Veracyte, Inc.
|
$3.36B | +0.5% | +16.0% | 29.9 | 8.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$232.67B | +8.6% | +14.5% | 33.9 | 1.3% |
|
DHR
Danaher Corp /De/
|
$151.78B | -4.4% | +8.5% | 38.3 | 1.7% |
|
NTRA
Natera, Inc.
|
$47.86B | +44.9% | -2.8% | — | 3.0% |
|
A
Agilent Technologies, Inc.
|
$44.14B | +16.9% | +6.4% | 31.4 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCYT | +2.6% | -25.3% | +17.5% | -8.7% | +0.5% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +3.9% | -28.9% | +5.9% | -11.2% | -11.8% |
Key facts
CIK
1384101
CUSIP
92337F107
13F (30d)
335 filings
332 filers
Visit website
Investor relations